Abcellera Biologics Inc (ABCL)

$4.11 -0.02 (-0.48%)
Market Cap 1.24B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 4,800,800
Avg Vol 4,224,102
Day's Range N/A - N/A
Shares Out 299.34M
Stochastic %K 90%
Beta 0.73
Analysts Strong Sell
Price Target $9.00

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
DeMampCamp
DeMampCamp Jan. 9 at 1:18 AM
$ABCL Big year ahead, folks. The J.P. Morgan Healthcare Conference starts next week (Jan 14th), and I'm stoked to hear ABCL’s presentation. Additionally, ABCL is expected to advance its third internal molecule, ABCL688, into Phase 1 by mid-2026, alongside ABCL635 and ABCL575. Phase 1 readouts for ABCL635 and ABCL575 are anticipated in Q3 2026, could be a truly pivotal year for long-term holders. Cheers to everyone holding strong — enjoy the weekend.
1 · Reply
OnChainAce
OnChainAce Jan. 8 at 10:23 PM
$ABCL generational wealth loading.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jan. 8 at 8:15 PM
$ABCL
2 · Reply
Ed_Ng
Ed_Ng Jan. 8 at 8:01 PM
$ABCL you think you are right? 😂. So stupid. You sold at 4, then buy back for a swing trade. Now begging everyone to buy with nonsense AI posts, so you can take profit. LOL. This group is funny
0 · Reply
Stocktradesmoon
Stocktradesmoon Jan. 8 at 7:41 PM
$ABCL
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 8 at 7:34 PM
$ABCL THIS GUY IS NEVER RIGHT.... NEVER
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 8 at 7:31 PM
$ABCL STOCK IS HOLDING THE 4 LEVEL... TOMORROW WE COULD MARCH HIGHER...
0 · Reply
sogenerous
sogenerous Jan. 8 at 4:31 PM
$PRME $ABCL
3 · Reply
DeMampCamp
DeMampCamp Jan. 8 at 4:10 PM
$ABCL Looking great, morning consolidation before attempted the gap fill possibly?
0 · Reply
NorthShoreTrader2021
NorthShoreTrader2021 Jan. 8 at 3:35 PM
$ABCL Hey shorts on $ABCL 😳👀… that awkward moment when you’re sitting on about 50M shares short at ~$3-4 levels, and bulls are diamond-handing forever. Wanna cover those 50M-ish at $7? $11? Or wait for $15 and get margin-called? Ball’s in your court – cut losses now or let your broker do it for ya! 💎🙌 #ABCL #shortsqueeze
1 · Reply
Latest News on ABCL
AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 21 days ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 4 weeks ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 8, 2025, 1:37 PM EST - 4 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 12:23 AM EST - 6 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 2 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 7:16 PM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 2 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 3 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 4 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 4 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 5 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 7 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 8 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 8 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 8 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 8 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 9 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 10 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 11 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 11 months ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

DeMampCamp
DeMampCamp Jan. 9 at 1:18 AM
$ABCL Big year ahead, folks. The J.P. Morgan Healthcare Conference starts next week (Jan 14th), and I'm stoked to hear ABCL’s presentation. Additionally, ABCL is expected to advance its third internal molecule, ABCL688, into Phase 1 by mid-2026, alongside ABCL635 and ABCL575. Phase 1 readouts for ABCL635 and ABCL575 are anticipated in Q3 2026, could be a truly pivotal year for long-term holders. Cheers to everyone holding strong — enjoy the weekend.
1 · Reply
OnChainAce
OnChainAce Jan. 8 at 10:23 PM
$ABCL generational wealth loading.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jan. 8 at 8:15 PM
$ABCL
2 · Reply
Ed_Ng
Ed_Ng Jan. 8 at 8:01 PM
$ABCL you think you are right? 😂. So stupid. You sold at 4, then buy back for a swing trade. Now begging everyone to buy with nonsense AI posts, so you can take profit. LOL. This group is funny
0 · Reply
Stocktradesmoon
Stocktradesmoon Jan. 8 at 7:41 PM
$ABCL
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 8 at 7:34 PM
$ABCL THIS GUY IS NEVER RIGHT.... NEVER
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 8 at 7:31 PM
$ABCL STOCK IS HOLDING THE 4 LEVEL... TOMORROW WE COULD MARCH HIGHER...
0 · Reply
sogenerous
sogenerous Jan. 8 at 4:31 PM
$PRME $ABCL
3 · Reply
DeMampCamp
DeMampCamp Jan. 8 at 4:10 PM
$ABCL Looking great, morning consolidation before attempted the gap fill possibly?
0 · Reply
NorthShoreTrader2021
NorthShoreTrader2021 Jan. 8 at 3:35 PM
$ABCL Hey shorts on $ABCL 😳👀… that awkward moment when you’re sitting on about 50M shares short at ~$3-4 levels, and bulls are diamond-handing forever. Wanna cover those 50M-ish at $7? $11? Or wait for $15 and get margin-called? Ball’s in your court – cut losses now or let your broker do it for ya! 💎🙌 #ABCL #shortsqueeze
1 · Reply
Ed_Ng
Ed_Ng Jan. 8 at 3:09 PM
$ABCL back to 3.4 range
1 · Reply
Ed_Ng
Ed_Ng Jan. 8 at 2:50 PM
$ABCL just 10% drop today. All of the bulls yesterday will be silent. As normal for this penny stock
1 · Reply
estatebuyersmia
estatebuyersmia Jan. 8 at 11:52 AM
$ABCL https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
0 · Reply
UncleTomFlorida
UncleTomFlorida Jan. 8 at 1:59 AM
$ABCL
0 · Reply
UncleTomFlorida
UncleTomFlorida Jan. 8 at 1:47 AM
$ABCL Last trade of ABCL was $4.29. It will be interesting to see what happens between now and Jan 14 when the company presents at the JP Morgan Healthcare Conference. Since the beginning of the year, top executives in legal, finance have been scooping up $MILLIONS in stock. So something is up. Add to this a short squeeze and it will be ever so much fun.
1 · Reply
LongTermInvestingCKramer
LongTermInvestingCKramer Jan. 7 at 8:25 PM
$ABCL I'm no chart expert but this looks like clear bullish sign.
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 7 at 8:12 PM
$ABCL THANK YOU $PRME $ABCL $RXRX ACCORDING TO ED_NG SCAM STOCKS!
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jan. 7 at 8:11 PM
$ABCL 😀 Patience pays off been buy every drop. Feeling good right now
0 · Reply
DeMampCamp
DeMampCamp Jan. 7 at 8:10 PM
$ABCL
1 · Reply
LotOfAction
LotOfAction Jan. 7 at 8:09 PM
$ABCL almost that time again
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 7 at 7:51 PM
$ABCL SHORTS BETTER COVER...
1 · Reply
estatebuyersmia
estatebuyersmia Jan. 7 at 7:38 PM
$ABCL ED_NG lives in a fantasy world, when the stock was in the mid 3's he kept ranting the stock was going back to under two. He said it multiple times. Now he flip flops and said he never said it wasnt going over 4.HE SHOULD JUST CAPITULATE AND STOP BASHING THID STOCK, FIND A HOBBY...
0 · Reply